FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3020007291> ?p ?o ?g. }

• W3020007291 abstract "Abstract Background Scleromyxedema is a rare, idiopathic, generalised mucinosis with a progressive and unpredictable course, and has both cutaneous and systemic manifestations. It typically presents with a diffuse cutaneous papular eruption causing extensive skin tightening which can be severely debilitating and is one of four diagnostic criteria for scleromyxedema. The remaining criteria being evidence of histological mucinosis, presence of an IgG lambda monoclonal gammopathy and the absence of thyroid disease. Due to its rarity and subsequent lack of controlled studies, there remains no current standardised treatment. Relevant literature consists of case studies and series trialling use of a variety of immunosuppressive therapies with varying levels of success. Intravenous immunoglobulin (IVIG) has been shown to be the most effective therapeutic option so far and we report here further success following its use. Methods A previously healthy 54-year-old Caucasian woman presented to dermatology with widespread cutaneous mucinous deposits on her entire body with sparing of the anterior chest and abdomen. She was trialled on both topical and oral steroids as well as oral and subcutaneous methotrexate, but all had negligible benefit and her modified Rodnan’s skin score (mRss), an objective assessment of skin thickness, remained significantly raised at 29/51. A punch skin biopsy showed prominent superficial histiocytic mucinosis, and serum electrophoresis revealed an IgG lambda gammopathy, consistent with a diagnosis of scleromyxedema. To complete the diagnostic criteria, she also tested negative for thyroid dysfunction. In terms of systemic manifestations, she later presented with unexplained intermittent dysphagia and occasional reflux, which have previously been reported as common symptoms in 60-90% of patients with scleromyxoedema. Monthly treatment with IVIG at a dosage of 2 gram/kg over 2 days was started. Results The IVIG showed marked clinical success and minimal side effects. After four cycles, skin thickening was reversed and her mRss dropped to zero. Mycophenolate mofetil (MMF) (2g daily) was introduced after three months, to allow six-weekly IVIG infusions. Conclusion This report further supports the growing literature that IVIG is a safe and effective treatment for scleromyxedema. The underlying mechanism of how it treats scleromyxoedema is yet to be elucidated with only proposed mechanisms so far, such as the neutralisation of pathogenic autoantibodies. It is, however, important to acknowledge that IVIG is very expensive and in limited supply and requires time-consuming administration. To combat these downfalls, we had trialled the potential use of MMF as an IVIG ‘sparing agent’ to optimise patient convenience and reduce cost, without compromising clinical care. Unfortunately, the MMF was only successful for the first few months and was subsequently stopped due to adverse effects. Nevertheless, we still anticipate this work will provide further evidence for the approval of IVIG for the future treatment of scleromyxedema. Disclosures C. Lin None. F.A.H. Cooles None. S.J. Meggitt None. B. Griffiths None." @default.
• W3020007291 created "2020-05-01" @default.
• W3020007291 creator A5008642034 @default.
• W3020007291 creator A5021058250 @default.
• W3020007291 creator A5021451679 @default.
• W3020007291 creator A5052571277 @default.
• W3020007291 date "2020-04-01" @default.
• W3020007291 modified "2023-09-23" @default.
• W3020007291 title "P39 Treatment of scleromyxedema with intravenous immunoglobulin" @default.
• W3020007291 doi "https://doi.org/10.1093/rheumatology/keaa111.038" @default.
• W3020007291 hasPublicationYear "2020" @default.
• W3020007291 type Work @default.
• W3020007291 sameAs 3020007291 @default.
• W3020007291 citedByCount "0" @default.
• W3020007291 crossrefType "journal-article" @default.
• W3020007291 hasAuthorship W3020007291A5008642034 @default.
• W3020007291 hasAuthorship W3020007291A5021058250 @default.
• W3020007291 hasAuthorship W3020007291A5021451679 @default.
• W3020007291 hasAuthorship W3020007291A5052571277 @default.
• W3020007291 hasBestOaLocation W30200072911 @default.
• W3020007291 hasConcept C126322002 @default.
• W3020007291 hasConcept C142724271 @default.
• W3020007291 hasConcept C159654299 @default.
• W3020007291 hasConcept C16005928 @default.
• W3020007291 hasConcept C163864487 @default.
• W3020007291 hasConcept C203014093 @default.
• W3020007291 hasConcept C2775934546 @default.
• W3020007291 hasConcept C2776148967 @default.
• W3020007291 hasConcept C2776364478 @default.
• W3020007291 hasConcept C2779427971 @default.
• W3020007291 hasConcept C2780101021 @default.
• W3020007291 hasConcept C2780439664 @default.
• W3020007291 hasConcept C2909204789 @default.
• W3020007291 hasConcept C526584372 @default.
• W3020007291 hasConcept C542903549 @default.
• W3020007291 hasConcept C71924100 @default.
• W3020007291 hasConceptScore W3020007291C126322002 @default.
• W3020007291 hasConceptScore W3020007291C142724271 @default.
• W3020007291 hasConceptScore W3020007291C159654299 @default.
• W3020007291 hasConceptScore W3020007291C16005928 @default.
• W3020007291 hasConceptScore W3020007291C163864487 @default.
• W3020007291 hasConceptScore W3020007291C203014093 @default.
• W3020007291 hasConceptScore W3020007291C2775934546 @default.
• W3020007291 hasConceptScore W3020007291C2776148967 @default.
• W3020007291 hasConceptScore W3020007291C2776364478 @default.
• W3020007291 hasConceptScore W3020007291C2779427971 @default.
• W3020007291 hasConceptScore W3020007291C2780101021 @default.
• W3020007291 hasConceptScore W3020007291C2780439664 @default.
• W3020007291 hasConceptScore W3020007291C2909204789 @default.
• W3020007291 hasConceptScore W3020007291C526584372 @default.
• W3020007291 hasConceptScore W3020007291C542903549 @default.
• W3020007291 hasConceptScore W3020007291C71924100 @default.
• W3020007291 hasLocation W30200072911 @default.
• W3020007291 hasOpenAccess W3020007291 @default.
• W3020007291 hasPrimaryLocation W30200072911 @default.
• W3020007291 hasRelatedWork W13209929 @default.
• W3020007291 hasRelatedWork W14013891 @default.
• W3020007291 hasRelatedWork W14028861 @default.
• W3020007291 hasRelatedWork W14950300 @default.
• W3020007291 hasRelatedWork W18249187 @default.
• W3020007291 hasRelatedWork W3144721 @default.
• W3020007291 hasRelatedWork W7820156 @default.
• W3020007291 hasRelatedWork W8398951 @default.
• W3020007291 hasRelatedWork W9662656 @default.
• W3020007291 hasRelatedWork W11929683 @default.
• W3020007291 isParatext "false" @default.
• W3020007291 isRetracted "false" @default.
• W3020007291 magId "3020007291" @default.
• W3020007291 workType "article" @default.